| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TAC1 |
| Uniprot No | P20366 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-129aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMEEIGA NDDLNYWSDW YDSDQIKEEL PEPFEHLLQR IARRPKPQQF FGLMGKRDAD SSIEKQVALL KALYGHGQIS HKRHKTDSFV GLMGKRALNS VAYERSAMQN YERRR |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TAC1重组蛋白研究的模拟参考文献示例(非真实文献，仅供格式参考)：
1. **文献名称**: "Recombinant TAC1 Protein Expression and Its Role in Neuroinflammatory Signaling"
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化TAC1重组蛋白，验证其与NK1受体的结合活性，证明其在体外可激活炎症通路，提示TAC1可能在神经性疼痛中发挥作用。
2. **文献名称**: "TAC1-derived Peptides Promote Cancer Metastasis via ERK Pathway Activation"
**作者**: Li X, et al.
**摘要**: 通过哺乳动物细胞系统制备重组TAC1蛋白，发现其切割产物P物质通过激活ERK信号通路增强乳腺癌细胞迁移，为靶向TAC1的肿瘤治疗提供依据。
3. **文献名称**: "Structural Characterization of Recombinant TAC1 and Its Interaction with GPCRs"
**作者**: Garcia R, et al.
**摘要**: 利用杆状病毒-昆虫细胞系统表达TAC1重组蛋白，通过X射线晶体学解析其结构，揭示其与G蛋白偶联受体(如NK1R)的特异性结合域。
---
**提示**：实际文献需通过PubMed/Google Scholar等平台检索，可使用关键词“TAC1 recombinant protein”或“TAC1 expression and function”。
TAC1 recombinant protein is derived from the TAC1 gene, which encodes a precursor protein known as substance P precursor or tachykinin precursor 1. Tachykinins are a family of neuropeptides involved in diverse physiological processes, including pain transmission, inflammation, immune response, and cell proliferation. The TAC1 gene product is proteolytically processed to generate multiple bioactive peptides, such as substance P (SP), neurokinin A (NKA), neuropeptide K (NPK), and neuropeptide γ (NPγ). These peptides exert their functions by binding to G protein-coupled receptors (NK1R, NK2R, NK3R), triggering intracellular signaling pathways.
The recombinant TAC1 protein is typically produced in vitro using expression systems like *E. coli*, yeast, or mammalian cells, enabling large-scale studies of its structure and function. Its production involves cloning the TAC1 gene into expression vectors, optimizing codon usage for the host system, and purifying the protein via affinity chromatography. Recombinant versions allow researchers to investigate tachykinin-related mechanisms in diseases such as chronic pain, neurodegenerative disorders, cancer, and inflammatory conditions. For example, substance P is implicated in pain sensitization and neurogenic inflammation, making TAC1 a potential therapeutic target.
Interest in TAC1 recombinant protein also stems from its role as a biomarker in clinical research. Altered TAC1 expression has been observed in cancer progression, psychiatric disorders, and gastrointestinal diseases. By studying the recombinant protein, researchers can develop inhibitors or modulators targeting tachykinin pathways, paving the way for novel drugs. Additionally, its use in structural studies aids in understanding peptide-receptor interactions, guiding the design of selective agonists or antagonists. Overall, TAC1 recombinant protein serves as a vital tool for both basic research and translational applications in biomedicine.
×
